Academic medicine, summarized in a few publications

Thread 🧵

#AcademicTwitter #MedTwitter Understanding academic medical centers: Simone's maxims

pubmed.ncbi.nlm.nih.gov/10499593/
@AACR

Talk from @DigiaimoRon on billing and coding in #radonc at #ACRO2023.
Cumulative payments in the field are down 30% from 2007 to 2023. #radonc CPT codes are under 77xxx, historically under radiology.

Coding rules from CMS change.
Eg, CT sim and 3D plan historically could not be billed on same day.

What are the arguments for and against the combination of conventionally fractionated radiotherapy (2 Gy / fx; ~10-45 fractions) with concurrent immunotherapy (ipi, nivo, etc)?

A thread. 🧵

https://twitter.com/NicholasZaorsky/status/1613971357913747457

Proponents of combination therapy will reference:
1, numerous studies of RT + ICI, all seemingly safe
2, ICI is the best option if cisplatin ineligible
3, RT is immunostimulatory, should boost effect of ICI, RT + ICI is synergistic

Radiotherapy for renal cell carcinoma: current status and future directions

#RadOnc #kcsm #KidneyCancer @ASTRO_org @ESTRO_RT @ARRO_org @RadoncUh

Thread🧵 Thanks to @_ShankarSiva @DrAlexLouie @rob_uzzo @uretericbud @whallradonc @LPonsky @LeilaTchelebi for improving quality of this talk.

Thanks to @AmarUKishan @UCLA for invite to present.

https://twitter.com/AmarUKishan/status/1598671748383531008

How to write a research abstract for presentation at a meeting

Presented at #ASTRO22 @ASTRO_org
@pipcosper #radonc

Tweetorial 🧵 This thread will review the key components of each abstract section and provide examples of some of the highest scored abstracts at #ASTRO22

Since our Twitter audience is diverse, I will also highlight key features in recent @NEJM NordICC abstract:
nejm.org/doi/full/10.10…

What is the ideal management of biochemically (PSA) recurrent prostate cancer after prostatectomy?

Here are case scenarios that place treatment strategies in perspective.

This will be a thread of subthreads. 🧵

#PCSM #RadOnc

This thread is a continuation of this work:

@NatRevUrol
rdcu.be/csM2z
pubmed.ncbi.nlm.nih.gov/34363040/
x.com/nicholaszaorsk…

Oral boards for #RadOnc are approaching. Here is advice to anyone taking the exam.

@ARRO_org @ASTRO_org @ACRORadOnc @ACROresident 1, #RadOnc oral boards are the most clinically relevant exams (vs rad bio, physics, written exam, inservice, etc).
Many of the questions about management come straight from @NCCN guidelines, so use these as a primary reference.

How to run a meeting at an academic medical center

🧵 Originally, this presentation was for our oncology trainees, and we figured we would share it on #AcademicTwitter #MedTwitter to maximize the impact of your meetings.

Thanks to @DrSpratticus @LeilaTchelebi @EricLehrer @TimShowalter1 @RonaldChenMD @nytimes @HarvardBiz et al

Health services research using United States cancer databases

Here is everything you want to know about @theNCI SEER, @AmericanCancer @AmCollSurgeons NCDB, and newer claims databases for clinical research in oncology

🧵 First, many thanks to these great people for helping me with the material

Advice for mentees (eg, med students, residents, junior faculty) who want to publish a manuscript 1. Research your mentor.

Know their body of work, content expertise
Do they routinely work w trainees?
Ask mentees who have worked w this mentor what the experience is like

Guide to writing a medical research manuscript

bit.ly/ZaorskyManuscr…

Here is advice after writing, reading, and reviewing 1000+ manuscripts.

#MedTwitter Why do we do medical research?

There are at least two problems with medicine:
(1) in 100 years, half of it will be proven to be false;
(2) we don’t know which half.

Real world data vs a randomized controlled trial for comparative effectiveness research.

If you change analytical methods of the real world data, can you generate any conclusion that you want?

Yes!

The randomized controlled trial remains the gold standard.

@ASTRO_org #ASTRO21 Comparative effectiveness research evaluates the efficacy of one treatment relative to another, treatment A vs treatment B.

For example:
Radiation vs surgery for prostate cancer
Ivermectin vs placebo for COVID
Streptomycin for TB (1st RCT!, ncbi.nlm.nih.gov/pmc/articles/P…)

Impact of radiation therapy facility volume on survival in patients with cancer.

@LeilaTchelebi @wedney2017 @NirajGusani @PennStHershey

Via @JournalCancer @ACS_Research

acsjournals.onlinelibrary.wiley.com/doi/full/10.10…
pubmed.ncbi.nlm.nih.gov/34398470/ Facility volume has been explored as a surrogate of quality of care in medicine.

pubmed.ncbi.nlm.nih.gov/12230353/
@AnnalsofIM

Salvage therapy for prostate cancer after prostatectomy: international consensus on evaluation and management

@NatRevUrol

rdcu.be/csM2z
pubmed.ncbi.nlm.nih.gov/34363040/
#PCSM Since the 2000s, the use of radical prostatectomy has been increasing for prostate cancer (vs external beam and brachytherapy).

@EUplatinum
pubmed.ncbi.nlm.nih.gov/27597241/

Publication productivity and academic rank in medicine.

Via @AcadMedJournal
ncbi.nlm.nih.gov/pubmed/32028299
From @EricLehrer @DrEmmaHolliday @PennStHershey @penn_state

[tweetorial] on the impact of h-index and m-index on promotion/tenure.

#academicmedicine #MedEd #scholarship @AcadMedJournal @EricLehrer @DrEmmaHolliday @PennStHershey @penn_state Are metrics for promotion and tenure at academic institutions easy to understand?

In this thread, I will compile my medical illustrations in oncology and #RadOnc.

Many are from textbook w @DanTrifMD
amazon.com/Absolute-Clini…
based on @ARRO_org study guide for board exams.

A picture is worth 1000 words.
Here is oncology in a few pics. @DanTrifMD @ARRO_org @SpringerNature Starting with pediatrics:
Rhabdomyosarcoma treatment paradigm for cancers of head/neck depends on parameningeal vs non-parameningeal location. PM is an unfavorable site, affects stage. #sarcoma #HNCSM